Sonim Q3 revenue $16.2M (+45% seq), net loss narrows to $4.8M; asset sale to NEXA for $15M on track for Q4 close

DNA X, Inc.

2025-Q3 EPS reported -$19.14 revenue$44,125,000

Net revenue $16.2M, up 45% sequentially from Q2; GAAP net loss $4.8M vs $7.5M in Q2.
Adjusted EBITDA negative $2.0M, improving from negative $3.2M in Q2.
Entered definitive agreement to sell substantially all assets to NEXA for $15M cash plus up to $5M earn-out; expected close late Q4 2025.
Reverse stock split 1-for-18 effected Oct 27, 2025 to regain Nasdaq compliance.
Cash $2.1M; received $4.8M net proceeds from equity offerings during Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.